Exhaled breath condensate biomarkers in COPD.

Publisher: European Respiratory Society Country of Publication: England NLM ID: 8803460 Publication Model: Print Cited Medium: Internet ISSN: 1399-3003 (Electronic) Linking ISSN: 09031936 NLM ISO Abbreviation: Eur Respir J Subsets: MEDLINE

Publication: Sheffield, United Kingdom : European Respiratory Society
Original Publication: Copenhagen : Published jointly by the Society and Munksgaard, 1988-

Biomarkers/*analysis ; Breath Tests/*methods ; Pulmonary Disease, Chronic Obstructive/*diagnosis; Asthma/diagnosis ; Clinical Trials as Topic ; Cytokines/analysis ; Exhalation ; Humans ; Hydrogen-Ion Concentration ; Mass Spectrometry/methods ; Phenotype ; Prostaglandins/analysis ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Pulmonary Medicine/methods ; Respiration Disorders/diagnosis ; Respiratory System/chemistry ; Respiratory System/physiopathology

Biomarkers in chronic obstructive pulmonary disease may be useful in aiding diagnosis, defining specific phenotypes of disease, monitoring exacerbations and evaluating the effects of drugs. Exhaled breath condensate is a noninvasive means of sampling the airways, allowing biomarkers of airway inflammation and oxidative stress to be measured. In the present review, the use of exhaled breath condensate biomarkers in chronic obstructive pulmonary disease is explored and potential applications in diagnosis, disease phenotyping, exacerbation monitoring and clinical trials are considered. Exhaled breath condensate biomarkers are comprehensively reviewed in terms of method validation, reproducibility, disease specificity and sensitivity to detect changes in airway inflammation. The commonly used exhaled breath condensate methodologies in chronic obstructive pulmonary disease patients are shown to have considerable variability, due to technical issues concerning both sample collection and analysis. Despite these issues, there is still data to support the use of exhaled breath condensate biomarkers for monitoring chronic obstructive pulmonary disease exacerbations and the response to pharmacological intervention. Further improvements to sample collection and analysis methods will improve the sensitivity of these biomarkers. The use of cytokine arrays, mass spectrometry and nuclear magnetic resonance profiling of exhaled breath condensate has opened a new avenue for analysis, as hypothesis generation from such profiling may lead to further selection of biomarkers for specific analysis.

96

Comment in: Eur Respir J. 2009 May;33(5):1238. (PMID: 19407061)

0 (Biomarkers)
0 (Cytokines)
0 (Prostaglandins)

Date Created: 20080802 Date Completed: 20081118 Latest Revision: 20220330

20221213

10.1183/09031936.00116107

18669788